BCAB
Price
$0.38
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
22.43M
39 days until earnings call
DNLI
Price
$14.10
Change
-$0.39 (-2.69%)
Updated
Jun 27 closing price
Capitalization
2.05B
32 days until earnings call
Interact to see
Advertisement

BCAB vs DNLI

Header iconBCAB vs DNLI Comparison
Open Charts BCAB vs DNLIBanner chart's image
BioAtla
Price$0.38
Change-$0.00 (-0.00%)
Volume$389.59K
Capitalization22.43M
Denali Therapeutics
Price$14.10
Change-$0.39 (-2.69%)
Volume$4.08M
Capitalization2.05B
BCAB vs DNLI Comparison Chart in %
Loading...
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCAB vs. DNLI commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Buy and DNLI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (BCAB: $0.38 vs. DNLI: $14.10)
Brand notoriety: BCAB and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 69% vs. DNLI: 276%
Market capitalization -- BCAB: $22.43M vs. DNLI: $2.05B
BCAB [@Biotechnology] is valued at $22.43M. DNLI’s [@Biotechnology] market capitalization is $2.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, both BCAB and DNLI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 2 TA indicator(s) are bullish while DNLI’s TA Score has 2 bullish TA indicator(s).

  • BCAB’s TA Score: 2 bullish, 8 bearish.
  • DNLI’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than BCAB.

Price Growth

BCAB (@Biotechnology) experienced а -4.33% price change this week, while DNLI (@Biotechnology) price change was +1.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

BCAB is expected to report earnings on Aug 07, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.05B) has a higher market cap than BCAB($22.4M). DNLI YTD gains are higher at: -30.815 vs. BCAB (-35.047). BCAB has higher annual earnings (EBITDA): -66.23M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. BCAB (32.4M). BCAB has less debt than DNLI: BCAB (554K) vs DNLI (48.6M). BCAB has higher revenues than DNLI: BCAB (11M) vs DNLI (0).
BCABDNLIBCAB / DNLI
Capitalization22.4M2.05B1%
EBITDA-66.23M-505.16M13%
Gain YTD-35.047-30.815114%
P/E RatioN/AN/A-
Revenue11M0-
Total Cash32.4M818M4%
Total Debt554K48.6M1%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
63
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABDNLI
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGVIX14.180.15
+1.07%
Causeway Global Value Inst
OTCJX32.530.29
+0.90%
MFS Mid Cap Growth R4
BIALX29.920.19
+0.64%
Brown Advisory Global Leaders Investor
IJEAX13.310.04
+0.30%
VY® JPMorgan Emerging Markets Equity A
TCMGX21.300.01
+0.05%
Nuveen Quant Mid Cap Growth A

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with NVO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then NVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
+2.37%
NVO - BCAB
39%
Loosely correlated
+1.20%
CRSP - BCAB
38%
Loosely correlated
N/A
CTMX - BCAB
37%
Loosely correlated
-2.60%
DNLI - BCAB
37%
Loosely correlated
-2.69%
OVID - BCAB
36%
Loosely correlated
-11.95%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-2.69%
BEAM - DNLI
61%
Loosely correlated
-1.98%
NRIX - DNLI
59%
Loosely correlated
+0.17%
RGNX - DNLI
58%
Loosely correlated
-4.11%
ARWR - DNLI
57%
Loosely correlated
+0.06%
ATXS - DNLI
57%
Loosely correlated
N/A
More